Ipsen SA (IPN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA (IPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 7
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13
Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ipsen SA, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18
Ipsen Acquires Oncology Assets from Merrimack Pharma 20
Venture Financing 22
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24
Rhythm Pharma Raises US$33 Million In Series B Financing 26
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28
Rhythm Pharma Raises US$9.5 Million In Venture Financing 30
Partnerships 31
Arix Bioscience and Ipsen Enter into Co-Development Agreement 31
Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32
Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33
Ipsen Partners with Oncodesign 34
Ipsen Enters into Research Agreement with PeptiMimesis 35
Ipsen Enters into Research Agreement with Aepodia 36
Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37
Ipsen Enters into Research Agreement with Interprotein 38
Ipsen and EpiVax Enter into Partnership 39
Ipsen Enters into Research Agreement with Hannover Medical School 40
Ipsen Enters into Research Agreement with Harvard University 41
Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 42
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 43
Ipsen Extends Distribution Agreement with Galderma for Dysport 44
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 46
Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 47
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 48
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 49
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 50
Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinsons Disease 51
Ipsen Extends Distribution Agreement With Galderma For Dysport 53
Oncodesign Enters into Research Agreement with Ipsen 54
Licensing Agreements 55
Ipsen Enters into Licensing Agreement with MD Anderson 55
Merrimack Pharma Enters into Licensing Agreement with Ipsen 56
Ipsen Amends Licensing Agreement with Exelixis 57
Ipsen Enters into Licensing Agreement with 3B Pharma 58
Ipsen Enters into Licensing Agreement with Telesta Therapeutics 59
Lexicon Pharma Expands Licensing Agreement with Ipsen 60
Otonomy Enters into Licensing Agreement with Ipsen 61
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 62
Ipsen Enters into Licensing Agreement with Probi 64
Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 65
Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 66
Equity Offering 67
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 67
Debt Offering 69
Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 69
Asset Transactions 70
Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 70
Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For US$300 Million 72
Acquisition 74
Ipsen to Acquire Equity Stake in Akkadeas Pharma 74
Ipsen Acquires Canbex Therapeutics 75
Ipsen Acquires OctreoPharm Sciences for USD57 Million 76
Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 77
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 79
Ipsen SA - Key Competitors 80
Ipsen SA - Key Employees 81
Ipsen SA - Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Affiliate 85
Joint Venture 85
Recent Developments 86
Financial Announcements 86
Feb 15, 2018: Ipsen Delivers Strong 2017 Results with 21.1%1 Sales Growth and Core Operating Margin Increase of 3.4 Points and Expects Significant Further Growth in Sales and Margin in 2018 86
Jul 27, 2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017 88
Apr 27, 2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1 96
Feb 23, 2017: Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017 99
Corporate Communications 107
Mar 13, 2018: Ipsen Announces Executive Leadership Appointments 107
Jan 26, 2018: Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer 108
Jan 12, 2018: Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America 109
Apr 14, 2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer 110
Feb 06, 2017: Ipsen announces appointment of Dr. Sotirios G. Stergiopoulos as Head of Global Medical Affairs 111
Jan 20, 2017: Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises 112
Product News 113
09/18/2017: U.S. FDA Approves New Indication for Ipsens Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome 113
09/04/2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress 114
07/21/2017: Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 115
07/03/2017: Somatuline Autogel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors 116
06/01/2017: Ipsen To Present New Data of Lanreotide at ASCO 117
06/01/2017: Ipsen To Present New Data on Investigational Compound Lu-OPS201 at ASCO 118
05/01/2018: Novel Theranostic Approach for Treating Pancreatic Cancer Patients Shows Promise 119
04/17/2017: Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research 120
03/09/2017: Ipsen announces data presentation on lanreotide (Somatuline Autogel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 121
03/09/2017: Ipsen announces presentation on the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 123
02/13/2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs) 124
01/15/2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018 125
Product Approvals 126
Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 126
Mar 28, 2017: NICE says pancreatic cancer drug is not cost effective for routine NHS use 128
Mar 13, 2017: Shires Onivyde Rejects For Use Within NHS Scotland 129
Mar 10, 2017: Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC 130
Clinical Trials 131
Jun 01, 2017: Ipsen Announces Presentation of New Data on Irinotecan at ASCO 131
May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis 132
Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies 133
Mar 27, 2017: Merrimack to Present Data on MM-398 at the 2017 American Association for Cancer Research Annual Meeting 135
Feb 01, 2017: Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis 136
Other Significant Developments 138
Jun 07, 2018: Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts 138
Appendix 139
Methodology 139
About GlobalData 139
Contact Us 139
Disclaimer 139

List Of Tables

List of Tables
Ipsen SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13
Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18
Ipsen Acquires Oncology Assets from Merrimack Pharma 20
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24
Rhythm Pharma Raises US$33 Million In Series B Financing 26
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28
Rhythm Pharma Raises US$9.5 Million In Venture Financing 30
Arix Bioscience and Ipsen Enter into Co-Development Agreement 31
Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32
Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33
Ipsen Partners with Oncodesign 34
Ipsen Enters into Research Agreement with PeptiMimesis 35
Ipsen Enters into Research Agreement with Aepodia 36
Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37
Ipsen Enters into Research Agreement with Interprotein 38
Ipsen and EpiVax Enter into Partnership 39
Ipsen Enters into Research Agreement with Hannover Medical School 40
Ipsen Enters into Research Agreement with Harvard University 41
Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 42
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 43
Ipsen Extends Distribution Agreement with Galderma for Dysport 44
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 46
Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 47
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 48
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 49
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 50
Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinsons Disease 51
Ipsen Extends Distribution Agreement With Galderma For Dysport 53
Oncodesign Enters into Research Agreement with Ipsen 54
Ipsen Enters into Licensing Agreement with MD Anderson 55
Merrimack Pharma Enters into Licensing Agreement with Ipsen 56
Ipsen Amends Licensing Agreement with Exelixis 57
Ipsen Enters into Licensing Agreement with 3B Pharma 58
Ipsen Enters into Licensing Agreement with Telesta Therapeutics 59
Lexicon Pharma Expands Licensing Agreement with Ipsen 60
Otonomy Enters into Licensing Agreement with Ipsen 61
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 62
Ipsen Enters into Licensing Agreement with Probi 64
Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 65
Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 66
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 67
Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 69
Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 70
Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For US$300 Million 72
Ipsen to Acquire Equity Stake in Akkadeas Pharma 74
Ipsen Acquires Canbex Therapeutics 75
Ipsen Acquires OctreoPharm Sciences for USD57 Million 76
Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 77
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 79
Ipsen SA, Key Competitors 80
Ipsen SA, Key Employees 81
Ipsen SA, Subsidiaries 83
Ipsen SA, Affiliate 85
Ipsen SA, Joint Venture 85

List Of Figures

List of Figures
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13

Ipsen SA (IPN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel

USD 250 View Report

Ipsen S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Ipsen S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Ipsen S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

Ipsen SA Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Ipsen SA Company Profile is a detailed strategic and analytical report on Ipsen SA. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Ipsen SA Strategic Analysis Review- Ipsen SA SWOT, Outlook, Operations and Financial Profile

Ipsen SA Company Profile provides strategic analysis of Ipsen SA Company in current market conditions. The companys business/ operational/growth strategies are analyzed in the unique research work. Growth opportunities available

USD 200 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available